Phibro Animal Net Income From Continuing Ops Over Time
| PAHC Stock | USD 52.26 0.99 1.93% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Phibro Animal Performance and Phibro Animal Correlation. Will Pharmaceuticals sector continue expanding? Could Phibro diversify its offerings? Factors like these will boost the valuation of Phibro Animal. Anticipated expansion of Phibro directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Phibro Animal data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 7.52 | Dividend Share 0.48 | Earnings Share 2.26 | Revenue Per Share | Quarterly Revenue Growth 0.209 |
The market value of Phibro Animal Health is measured differently than its book value, which is the value of Phibro that is recorded on the company's balance sheet. Investors also form their own opinion of Phibro Animal's value that differs from its market value or its book value, called intrinsic value, which is Phibro Animal's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Phibro Animal's market value can be influenced by many factors that don't directly affect Phibro Animal's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Phibro Animal's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Phibro Animal should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Phibro Animal's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare Phibro Animal Health and related stocks such as Alvotech, Organon, and Qilian International Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALVO | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (209.9 M) | (170 M) | (101.5 M) | (513.6 M) | (551.7 M) | (231.9 M) | (208.7 M) | (219.1 M) |
| OGN | 2.2 B | 2.2 B | 2.2 B | 2.2 B | 2.2 B | 2.2 B | 2.2 B | 2.2 B | 2.2 B | 3.2 B | 2.2 B | 1.4 B | 917 M | 585 M | 864 M | 777.6 M | 1.3 B |
| BGM | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 3.1 M | 1.4 M | (8.1 M) | (1.5 M) | (1.5 M) | (1.4 M) | (1.3 M) |
| AVDL | (46.5 M) | (46.5 M) | (46.5 M) | (46.5 M) | (89.5 M) | 40.7 M | (41.3 M) | 68.3 M | (95.3 M) | (33.2 M) | 7 M | (77.3 M) | (137.5 M) | (160.3 M) | (48.8 M) | (43.9 M) | (46.1 M) |
| AUPH | 0.0 | 0.0 | 0.0 | (2.5 M) | (19.4 M) | (18.6 M) | (23.3 M) | (70.8 M) | (64.1 M) | (123.8 M) | (102.7 M) | (181 M) | (108.2 M) | (77.2 M) | 5.8 M | 5.2 M | 5.4 M |
| TLRY | (100.8 M) | (100.8 M) | (100.8 M) | (100.8 M) | (100.8 M) | (100.8 M) | (100.8 M) | (100.8 M) | (100.8 M) | (100.8 M) | (336 M) | (434.1 M) | (1.4 B) | (222.4 M) | (2.2 B) | (2 B) | (1.9 B) |
| MNKD | (160.8 M) | (160.8 M) | (169.4 M) | (191.5 M) | (198.4 M) | (368.4 M) | 125.7 M | (117.3 M) | (87 M) | (51.9 M) | (57.2 M) | (80.9 M) | (87.4 M) | (31.3 M) | 27.6 M | 31.7 M | 33.3 M |
| EVO | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 84.1 M | 37.2 M | 6.3 M | 215.5 M | (175.7 M) | (83.9 M) | (196.1 M) | (176.5 M) | (167.6 M) |
| ANIP | (51.6 M) | (51.6 M) | (27.7 M) | 106 K | 28.7 M | 15.4 M | 3.9 M | (1.1 M) | 15.5 M | 6.1 M | (22.5 M) | (42.6 M) | (47.9 M) | 13.4 M | (18.5 M) | (16.7 M) | (15.8 M) |
| MD | 202.7 M | 218 M | 240.9 M | 280.5 M | 317.2 M | 335.7 M | 324.6 M | 320.4 M | 268.6 M | (1.2 B) | (9.6 M) | 108 M | 62.6 M | (60.4 M) | (99.1 M) | (89.2 M) | (84.7 M) |
Phibro Animal Health and related stocks such as Alvotech, Organon, and Qilian International Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Phibro Animal Health | PAHC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Glenpointe Centre East, |
| Exchange | NASDAQ Exchange |
USD 52.26
Check out Phibro Animal Performance and Phibro Animal Correlation. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Phibro Animal technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.